Cubicin(daptomycin)
Cubicin, Daptomycin (daptomycin) is a protein pharmaceutical. Daptomycin was first approved as Cubicin on 2003-09-12. It is used to treat bacteremia, bacterial infections, and bacterial skin diseases in the USA. It has been approved in Europe to treat bacteremia, bacterial endocarditis, bacterial skin diseases, gram-positive bacterial infections, and soft tissue infections.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Daptomycin (discontinued: Cubicin rf, Daptomycin)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Daptomycin
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| DAPTOMYCIN IN 0.9% SODIUM CHLORIDE | Baxter | N-213645 RX | 2023-02-27 | 4 products, RLD, RS |
| DAPTOMYCIN | Hikma Pharmaceuticals | N-209949 RX | 2017-10-20 | 1 products, RLD, RS |
| DAPTOMYCIN | Hikma Pharmaceuticals | N-217415 RX | 2023-01-30 | 2 products, RLD, RS |
| DAPTOMYCIN | Hospira | N-210282 RX | 2021-06-21 | 2 products, RLD, RS |
| DAPTOMYCIN | MAIA Biotechnology | N-217630 RX | 2024-11-21 | 1 products, RLD, RS |
| DAPTOMYCIN | Sagent Pharmaceuticals | N-208385 RX | 2017-09-12 | 1 products, RLD, RS |
Show 4 discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| cubicin | Export only | 2024-10-14 |
| cubicin rf | Export only | 2025-03-17 |
| daptomycin | ANDA | 2025-09-08 |
| daptomycin in sodium chloride | New Drug Application | 2025-04-30 |
| dapzura rt | New Drug Application | 2022-01-25 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| bacterial infections | — | D001424 | A49 |
| bacterial skin diseases | — | D017192 | — |
| bacteremia | EFO_0003033 | D016470 | R78.81 |
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Daptomycin, Daptomycin In 0.9% Sodium Chloride, Baxter Hlthcare Corp | |||
| 11173189 | 2041-03-11 | DP | U-3294 |
| Daptomycin, Daptomycin, Xellia Pharms Aps | |||
| 11759497 | 2038-08-28 | DP | |
| Daptomycin, Daptomycin, Hospira | |||
| 9655946 | 2033-09-11 | DP | U-3175 |
| 10357535 | 2033-09-11 | DP | U-3176 |
| Daptomycin, Cubicin, Cubist Pharms Llc | |||
| 9138456 | 2030-11-23 | DP | |
| 8003673 | 2028-09-04 | U-1180 | |
Clinical
Clinical Trials
120 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Staphylococcal infections | D013203 | — | A49.01 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Infections | D007239 | EFO_0000544 | — | — | 1 | — | — | — | 1 |
| Infectious skin diseases | D012874 | — | — | — | 1 | — | — | — | 1 |
| Soft tissue infections | D018461 | — | — | — | 1 | — | — | — | 1 |
| Bacteremia | D016470 | EFO_0003033 | R78.81 | — | 1 | — | — | — | 1 |
| Hematologic neoplasms | D019337 | — | — | — | 1 | — | — | — | 1 |
| Neoplasms | D009369 | — | C80 | — | 1 | — | — | — | 1 |
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Daptomycin |
| INN | daptomycin |
| Description | Daptomycin, sold under the brand name Cubicin among others, is a lipopeptide antibiotic used in the treatment of systemic and life-threatening infections caused by Gram-positive organisms.
|
| Classification | Small molecule |
| Drug class | aptamers, classical and mirror; antibiotics (Streptomyces strain) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CCCCCCCCCC(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H]1C(=O)NCC(=O)N[C@@H](CCCN)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@H](C)C(=O)N[C@@H](CC(=O)O)C(=O)NCC(=O)N[C@H](CO)C(=O)N[C@@H]([C@H](C)CC(=O)O)C(=O)N[C@@H](CC(=O)c2ccccc2N)C(=O)O[C@@H]1C |
Identifiers
| PDB | — |
| CAS-ID | 103060-53-3 |
| RxCUI | — |
| ChEMBL ID | CHEMBL387675 |
| ChEBI ID | 600103 |
| PubChem CID | 16129629 |
| DrugBank | DB00080 |
| UNII ID | NWQ5N31VKK (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Cubicin – Merck & Co
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
Daptomycin
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 16,910 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
13,232 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use